On this page
thoracic oncology
Explore " thoracic oncology" with insightful episodes like "Revolutionising Lung Cancer Healthcare with AI: Unlocking the Future", "Early Recovery After Surgery - Guidelines and Multidisciplinary Considerations", "Nature and nurture: lung cancer risk and implications for future screening", "Operability in Stage III NSCLC" and "NSCLC and KRAS Mutations" from podcasts like ""TOGA Podcast", "TOGA Podcast", "TOGA Podcast", "TOGA Podcast" and "TOGA Podcast"" and more!
Episodes (13)
Early Recovery After Surgery - Guidelines and Multidisciplinary Considerations
Nature and nurture: lung cancer risk and implications for future screening
Operability in Stage III NSCLC
NSCLC and KRAS Mutations
Treatment Considerations in ALK-Positive NSCLC
Brain metastases in NSCLC
NGS panels in lung cancer
The Management of Stage III NSCLC
Welcome to the Thoracic Oncology Group of Australasia Podcast series. Associate Professor Shankar Siva, Radiation Oncologist and current Cancer Council Victoria Colebatch Fellow who leads the SABR program at Peter MacCallum Cancer Centre discusses The Management of Stage III NSCLC in this podcast. Shankar is joined by Associate Professor Rachel Wong, Deputy Director of Oncology - Eastern Health, Adjunct Clinical Assoc Professor - Monash University and Clinical Research Fellow – WEHI and also Professor Drew Moghanaki, Chief of Thoracic Oncology, Department of Radiation Oncology at UCLA, Stanley Lezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research, Co-Director Greater Los Angeles Lung Precision Oncology Program and Co-Director Greater Los Angeles CSP NODES Program also joins us today. Our focus today is on what defines inoperable NSCLC, patient selection and how to manage the toxicities associated with treatment.
Thank you to AstraZeneca for sponsoring this podcast.
The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations
Welcome to the Thoracic Oncology Group of Australasia Podcast series. In this Podcast, we discuss early NSCLC management and treatment, particularly in light of how immunotherapy will impact surgical and respiratory medicine as the landscape evolves with new data. Dr Melissa Moore Medical Oncologist from St Vincent’s Melbourne and the TOGA Education Chair, is joined by Dr Katharine See, Director and Head of the Respiratory Medicine at the Northern Hospital, Melbourne and Mr Naveed Alam, Thoracic surgeon from St Vincent’s and Epworth, Melbourne to discuss and review the findings and implications for NSCLC patients.
Thank you to Roche for collaborating on this podcast.
Consider Every Trial as a TeleTrial
Barriers and facilitators and a unique insight into the patient benefits are discussed between Alexandra, patient advocate, teletrials participant and lung cancer survivor, Sabe Sabesan, medical oncologist from the ICON Cancer Centre in Townsville and co-chair of the Australian Teletrial program and the initial teletrials pilot in 2017-2020, and Craig Underhill, medical oncologist from Border Medical Oncology and Haematology in Albury/Wodonga. Incentive funding and harmonising governance requirements for TeleTrials in Australia will help solve many of these issues and continue to transform the way trials are managed. The benefits for patients and their families are clear and positively impact the future of trials in Australia.
Resources: https://wiki.cancer.org.au/australia/COSA:Teleoncology
https://www.digitalhealth.gov.au/healthcare-providers/initiatives-and-programs/telehealth
https://thoraciconcology.org.au/teletrials/
Supported by Takeda
Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.
The OJC Episode 33: Was Beethoven's death the result of medical malpractice?
The Oncology Journal Club - Delivering Oncology News Differently
The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 33 in our series The Oncology Journal Club.
Was Beethoven's death the result of medical malpractice? This week the OJC team tackle this crucial question plus the microbiome, trial design bias, five year outcomes for metastatic non-small-cell lung cancer and much more...
Hans Prenen gets us started by talking us through the connection between the gut microbiome and immune checkpoint inhibitors and Eva Segelov has a mega paper this week… She tackles our friend Bishal Gyawali’s paper addressing biases in study design that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale. Fascinating stuff!
Then Craig Underhill gives us his thoughts on Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer.
Today’s quick bites are as diverse as ever covering highlights from the AACR ASM, Fecal transplants for patients with cachexia, the TAPUR trial, Controversies in Thoracic Oncology, the costs of fear of cancer recurrence and much more.
With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!
Full bios and the list of all papers discussed are available on our website.
For the latest oncology news visit www.oncologynews.com.au and for regular oncology updates for healthcare professionals, subscribe for free to get the weekly The Oncology Newsletter.
The Oncology Podcast - An Australian Oncology Perspective
2020 Wrap: Remarkable Progress In Diagnosing & Treating Lung Cancer
Remarkable advances in screening, diagnosing and treating lung cancer are discussed in this Podcast. Associate Professor Nick Pavlakis, Medical Oncologists from Royal North Shore Hospital Sydney and Dr Emily Stone, Respiratory Physician from St Vincent’s Hospital Sydney join TOGA for a conversation about public health measures to ensure the survival increase we are seeing for patients with lung cancer continues to accelerate into this decade.
Sponsored with a Takeda Educational Grant.